Safflower Oil

Summary

Safflower Oil (CHEMBL1201660) is an approved unknown.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Clinical trials: 19

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201660
Name	Safflower Oil
Type	Unknown
Max phase	4

Also known as: Carthamus tinctorius seed oil, Liposyn, Safflower oil, SAFFLOWER OIL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
Not specified	16
PHASE2/PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01769092	PHASE2/PHASE3	TERMINATED	Clinical Trial of the Effects of DHA in the Treatment of Seizure Disorders
NCT00230113	PHASE2	COMPLETED	Effect of Omega-3 PUFA Supplementation in NAFLD Patients
NCT01047280	PHASE1	COMPLETED	Use of Conjugated Linoleic Acid as a Nutraceutical for Weight Loss in Humans
NCT00682318	Not specified	ACTIVE_NOT_RECRUITING	Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers
NCT05705648	Not specified	RECRUITING	Nutritional Management of Post COVID-19 Cognitive Symptoms
NCT01038440	Not specified	COMPLETED	Time and Dose Evaluation of Stearidonic Acid (SDA) to Eicosapentaenoic Acid (EPA) in Red Blood Cells
NCT01121471	Not specified	COMPLETED	Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women’s Diabetes Study)
NCT01233778	Not specified	COMPLETED	Canola Oil Multicentre Intervention Trial (COMIT)
NCT01250275	Not specified	COMPLETED	Effects of Canola Oil on Blood Vessel Function in Peripheral Arterial Disease
NCT01351012	Not specified	COMPLETED	Canola Oil Multicentre Intervention Trial
NCT01509469	Not specified	COMPLETED	The Effect of Different Macronutrients on Ileal Brake Activation
NCT01621087	Not specified	COMPLETED	Dietary Linoleic Acid for Secondary Prevention of Coronary Heart Disease and Death in the Sydney Heart Study: an RCT
NCT02091583	Not specified	COMPLETED	Canola Oil, Fibre and DHA Enhanced Clinical Trial
NCT03541031	Not specified	UNKNOWN	Micronutrients as Adjunctive Treatment for Bipolar Disorder
NCT03769779	Not specified	COMPLETED	Evaluation of the Benefits of FloraGLO™ Lutein on Skin Health
NCT04570995	Not specified	TERMINATED	Effect of Fish Oil on Athlete’s Executive Function
NCT05295719	Not specified	COMPLETED	Combining HIIT and n-3 PUFA to Reduce Inflammation and Improve Metabolic Health
NCT05297383	Not specified	WITHDRAWN	Combining HIIT and n-3 PUFA Supplementation to Reduce Inflammation and Improve Metabolic Health (HIIT&PUFA)
NCT06233825	Not specified	COMPLETED	Nutritional Intervention to Enhance Recovery After Arthroscopic Knee Surgery in Adults

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).